

1  
2 **1 Online supplement for:**  
3

4  
5 **2**  
6

7 **3 Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype**  
8

9 **4 SARS-CoV-2 specific T cells**  
10  
11

12 **5**  
13

14  
15 **6** Catherine Riou<sup>1,2,\*</sup>, Georgia Schäfer<sup>1,3,4</sup>, Elsa du Bruyn<sup>1,5</sup>, Rene T. Goliath<sup>1</sup>, Cari Stek<sup>1,5,6</sup>, Huihui  
16

17 **7** Mou<sup>7</sup>, Deli Hung<sup>8</sup>, Katalin A. Wilkinson<sup>1,5,9</sup>, Robert J. Wilkinson<sup>1,5,6,9</sup>  
18  
19

20 **8**  
21

22 **9** <sup>1</sup> Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease  
23 and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa  
24

25 <sup>2</sup> Division of Immunology, Department of Pathology, University of Cape Town, Observatory  
26 7925, South Africa

27 <sup>3</sup> International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town,  
28 Observatory 7925, South Africa

29 <sup>4</sup> Division of Medical Biochemistry and Structural Biology, Department of Integrative  
30 Biomedical Sciences, University of Cape Town, Observatory 7925, South Africa

31 <sup>5</sup> Department of Medicine, University of Cape Town, Observatory 7925, South Africa

32 <sup>6</sup> Department of Infectious Diseases, Imperial College London, W12 0NN, UK


33 <sup>7</sup> Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL  
34 33458, USA

35 <sup>8</sup> Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA  
36 92037, USA


37 <sup>9</sup> The Francis Crick Institute, London, NW1 1AT, UK  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Markers	Fluorochrome	Clone	Company	Cat. Number	Role
<b>CD3</b>	BV650	OKT3	BioLegend	317323	Lineage
<b>CD4</b>	BV785	OKT4	BioLegend	317428	
<b>CD8</b>	BV510	RPA-T8	BioLegend	301048	
<b>CD45RA</b>	Alexa 488	HI100	BioLegend	304114	Memory differentiation
<b>CD27</b>	PE-Cy5	1A4CD27	Beckman	6607107	
<b>CD38</b>	APC	HIT2	BD Bioscience	555462	Activation
<b>HLA-DR</b>	BV605	L243	BioLegend	307640	
<b>Ki67</b>	PerCP-Cy5.5	B56	BD Bioscience	561284	
<b>PD-1</b>	PE	EH12.2H7	BioLegend	329906	
<b>GrB</b>	BV421	GB11	BD Bioscience	563388	Cytotoxic potential
<b>IFN<math>\gamma</math></b>	BV711	4S.B3	BioLegend	502540	Functions
<b>TNF<math>\alpha</math></b>	PE-Cy7	MAB11	BioLegend	502930	
<b>IL-2</b>	PE/Dazzle™ 594	MQ1-17H12	BioLegend	500344	

**Supp table 1:** Description of the antibody panel used in the study.



**Supp Figure 1:** Gating strategy used to identify SARS-CoV-2 specific CD4 T cells and defined their phenotypic characteristics. **A-** Cell lineage. **B-** Phenotyping of total CD4 T cell and cytokine production in response to SARS-CoV-2 peptides. **C-** Phenotype of SARS-CoV-2 responding CD4 T cells in one participant with no symptom (left) and one COVID-19 confirmed participant (right). SARS-CoV-2-specific CD4 T cells (expressing any measured cytokine) are depicted in red.



Supp Figure 2: Comparison of magnitude of SARS-CoV-2-specific CD4 T cell response expressing TNF $\alpha$ , IL-2 or IFN $\gamma$  in participants exhibiting a detectable response to SARS-CoV-2 peptide pool. Each dot represent a participant and is color-coded according to clinical characteristics (Blue represents no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Black bars indicate medians. Statistical comparisons were performed using a nonparametric paired Friedman test.